UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number
000-30929
KERYX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
One Marina
Park Drive, 12
th
Floor, Boston, Massachusetts 02210
(617)
466-3500
(Address, including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the
box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
|
|
Rule
12g-4(a)(1)
|
|
☒
|
|
Rule
12g-4(a)(2)
|
|
☐
|
|
Rule
12h-3(b)(1)(i)
|
|
☒
|
|
Rule
12h-3(b)(1)(ii)
|
|
☐
|
|
Rule
15d-6
|
|
☐
|
|
Rule
15d-22(b)
|
|
☐
|
Approximate number of holders of record as of the certification or notice date: one (1)
Pursuant to the requirements of the Securities Exchange Act of 1934, Keryx Biopharmaceuticals, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
DATE:
|
|
December 26, 2018
|
|
|
|
BY:
|
|
/s/ Nicole R. Hadas
|
|
|
|
|
|
|
|
|
|
Name: Nicole R. Hadas
|
|
|
|
|
|
|
|
|
|
Title: President and Secretary (Principal Executive Officer)
|
